Organization
Hospital Universitario Vall d’Hebron
2 abstracts
Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
ADVANCED GLYCATION END PRODUCTS IN SYSTEMIC SCLEROSISOrg: IDIBELLL, IMIM (Hospital del Mar Medical Research Institute), Inflammation and Cartilage Cellular Research Group, Barcelona, Spain, Hospital del Mar, Barcelona, Spain, Hospital Universitario Vall d’Hebron, VHIR,